

## **BUSINESS NEWS – 15<sup>th</sup> September 2021**

### **[Diacurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy \(PAM inhibitor, formerly M2698, now DIACC3010\) from Merck](#)**

“We are confident that Diaccurate’s strong scientific background in developing novel mechanisms makes them the right partner to advance the development of M2698 in cancers with high unmet needs,” said Andreas Stickler, Chief Financial Officer and Head of Strategy, Business Development and Portfolio Management of the Healthcare business sector of Merck, KGaA, Darmstadt, Germany.

### **[CG Oncology and BMS to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® \(nivolumab\) in Metastatic Urothelial Cancer](#)**

“We are excited to initiate this important clinical trial with our lead oncolytic immunotherapy, CG0070, in combination with OPDIVO in metastatic urothelial cancer,” said Arthur Kuan, CEO of CG Oncology. “The clinical results to date for CG0070 make it a potential promising agent in bladder cancer and other tumor types, as monotherapy or in combination with immune checkpoint inhibitors.”

### **[Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies](#)**

“We are proud to partner with Genentech, given their commitment to patients and science in the cancer immunology field. This collaboration broadens Adaptimmune’s leadership position in developing allogeneic cell therapies building on our in-depth knowledge gained from our autologous clinical programs,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Through this collaboration, our platform will form the basis of a personalized allogeneic cell therapy vision, where any patient can receive a T-cell product for their cancer; a significant step towards our goal of making cell therapies both curative and mainstream.”